← All trials
NCT06412757
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2024
- Primary completion
- Feb 28, 2027
- Completion date
- Mar 31, 2027
- First posted
- May 14, 2024
- Last posted
- Aug 28, 2024
- Enrollment
- 224
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Deakin UniversityLead sponsor
- Deakin UniversityOfficial
- Deakin UniversitySponsor investigator
- University of MelbourneCollaborator
- Ramsay General HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.